Increased risk of breast cancer associated with CHEK2*1100delC.

doi:10.1200/JCO.2005.05.5160

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Increased risk of breast cancer associated with CHEK2*1100delC.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Jan 2007

Weischer Maren, Bojesen Stig Egil, Tybjaerg-Hansen Anne, Axelsson Christen Kirk, Nordestgaard Børge Grønne

Abstract excerpt

PURPOSE: CHEK2*1100delC heterozygosity has been associated with increased risk of breast, prostate, and colorectal cancer in case-control studies. We tested the hypothesis that CHEK2*1100delC heterozygosity in the general population increases the risk of cancer in general, and breast, prostate, and colorectal cancer in particular. PATIENTS AND METHODS: We performed a prospective study of 9,231 individuals from...

Topics

Adult
Aged
Aged, 80 and over
Breast Neoplasms
Case-Control Studies
Checkpoint Kinase 2
Colorectal Neoplasms
Denmark
Female
Gene Deletion
Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Heterozygote

Humans

Male

Middle Aged

Polymorphism, Genetic

Prostatic Neoplasms

Protein Serine-Threonine Kinases

Source

Open in PubMed

Identifiers

PMID: 16880452
DOI: 10.1200/JCO.2005.05.5160

Genes

CHEK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased risk of breast cancer associated with CHEK2*1100delC.PMID 16880452Read ↗

Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.Semantic proximity Read ↗

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.Semantic proximity Read ↗

CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.Semantic proximity Read ↗

CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls.Semantic proximity Read ↗

Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families.Semantic proximity Read ↗

A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.Semantic proximity Read ↗

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.Semantic proximity Read ↗

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.Semantic proximity Read ↗

The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.Semantic proximity Read ↗

CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.Semantic proximity Read ↗

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the <i>CHEK2*1100delC</i> Germline MutationSemantic proximity Read ↗

CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.